Novartis
Senior Scientist I/II, Hematology- Target Biology and Discovery
$94K–$183K
Cambridge (USA) · Senior · Full-time · Posted Oct 28, 2026
- Experience
- 3-5 years of relevant laboratory experience.
- Education
- Bachelor’s or master’s degree in biology, cellular or molecular biology, or a related scientific discipline.
About the job
Conduct target biology and discovery research to identify and validate therapeutic targets and advance early drug-discovery programs for hematologic cancers, particularly myeloid malignancies.
What you'll do
- Design and conduct studies on target identification, target validation, and mechanism of action using molecular and cellular approaches.
- Develop cellular assays and use disease-relevant hematologic models to address drug-discovery questions.
- Analyze and communicate results, contribute to project strategy, and maintain laboratory safety and documentation.
What they ask for
- Bachelor’s or master’s degree in biology, cellular or molecular biology, or a related scientific discipline.
- Hands-on experience designing, executing, and interpreting molecular and cellular biology experiments, including developing reproducible cellular assays.
- Proficiency in mammalian cell culture and molecular and protein-analysis methods such as cloning, qPCR, western blotting, and multiparameter flow cytometry.
- Ability to plan and troubleshoot experiments and communicate conclusions; strong scientific communication, organization, and collaboration skills.
Nice to have
- Experience with primary hematopoietic, immune, or patient-derived samples; CRISPR-based functional genomics; or medium- or high-throughput screening or profiling.
- Experience in pharmaceutical, biotechnology, or translational research, or familiarity with hematologic malignancies, particularly AML or MDS.
Pay
$93,800 - $174,200 (base salary); $98,700 - $183,400 (base salary)
Tools
CRISPR-based perturbation, gene knockdown/overexpression, chemical probes, western blotting, qPCR, imaging, cellular phenotyping, multiparameter flow cytometry
Model-written summary · the original posting is authoritative